INCY vs PTGX · P/E 14, rev $5.14B vs rev $269.8M
Incyte Corporation (INCY) versus Protagonist Therapeutics Inc (PTGX) — a side-by-side from cached financials, not a winner call.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Latest reported PTGX revenue for 2026-06-30 was $269.8M. Net income was $166.6M. PTGX currently screens at market cap $7.25B.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. PTGX currently screens at market cap $7.25B.
Not investment advice. Open the INCY and PTGX stock pages for the full models.
Not investment advice.